Ozanimod vs. Fingolimod for Relapsing-Remitting Multiple Sclerosis in Children and Adolescents
This study is looking at how well and how safely two medications, ozanimod and fingolimod, work for children and teenagers (ages 10 to 17) who have relapsing-remitting multiple sclerosis (RRMS). RRMS is a type of multiple sclerosis where symptoms come and go. You might be able to join if you have been diagnosed with RRMS and have had recent relapses (flare-ups of symptoms). The main goal is to see if one drug leads to fewer relapses over a period of up to two years. The study plans to include 194 participants, but its current recruitment status is unclear.
- Study design
- This is an interventional study comparing ozanimod, fingolimod, and a placebo (an inactive substance) in 194 participants. The specific phase of the study is not mentioned.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary endpoint, annualized relapse rate, will be measured for up to 2 years.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis
At a glance
Conditions
Where it's being run
33 sites across 23 statesStudy leadership
- Bristol-Myers Squibb · STUDY_DIRECTOR · Bristol-Myers Squibb
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Annualized relapse rate (ARR)Up to 2 years